Literature DB >> 22837348

Psychiatry, the pharmaceutical industry, and the road to better therapeutics.

H Christian Fibiger.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 22837348      PMCID: PMC3406532          DOI: 10.1093/schbul/sbs073

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


× No keyword cloud information.
  1 in total

1.  Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria project.

Authors:  Bruce N Cuthbert; Thomas R Insel
Journal:  Schizophr Bull       Date:  2010-10-07       Impact factor: 9.306

  1 in total
  17 in total

Review 1.  Can RDoC Help Find Order in Thought Disorder?

Authors:  Alex S Cohen; Thanh P Le; Taylor L Fedechko; Brita Elvevåg
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

2.  Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scale.

Authors:  Subramaniam Uthayathas; Christopher L Shaffer; Frank S Menniti; Christopher J Schmidt; Stella M Papa
Journal:  J Neurosci Methods       Date:  2013-02-16       Impact factor: 2.390

3.  [The Research Domain Criteria (Rdoc), reductionism and clinical psychiatry].

Authors:  Luc Faucher; Simon Goyer
Journal:  Rev Synth       Date:  2016-12

Review 4.  Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis.

Authors:  Dan Siskind; Victor Siskind; Steve Kisely
Journal:  Can J Psychiatry       Date:  2017-06-28       Impact factor: 4.356

Review 5.  Translating genome-wide association findings into new therapeutics for psychiatry.

Authors:  Gerome Breen; Qingqin Li; Bryan L Roth; Patricio O'Donnell; Michael Didriksen; Ricardo Dolmetsch; Paul F O'Reilly; Héléna A Gaspar; Husseini Manji; Christopher Huebel; John R Kelsoe; Dheeraj Malhotra; Alessandro Bertolino; Danielle Posthuma; Pamela Sklar; Shitij Kapur; Patrick F Sullivan; David A Collier; Howard J Edenberg
Journal:  Nat Neurosci       Date:  2016-10-26       Impact factor: 24.884

Review 6.  Neuroimaging biomarkers for early drug development in schizophrenia.

Authors:  Jason R Tregellas
Journal:  Biol Psychiatry       Date:  2013-10-04       Impact factor: 13.382

7.  Insights into functional pharmacology of α₁ GABA(A) receptors: how much does partial activation at the benzodiazepine site matter?

Authors:  Srđan Joksimović; Zdravko Varagic; Jovana Kovačević; Michael Van Linn; Marija Milić; Sundari Rallapalli; Tamara Timić; Werner Sieghart; James M Cook; Miroslav M Savić
Journal:  Psychopharmacology (Berl)       Date:  2013-05-18       Impact factor: 4.530

Review 8.  From adversity to psychosis: pathways and mechanisms from specific adversities to specific symptoms.

Authors:  Richard P Bentall; Paulo de Sousa; Filippo Varese; Sophie Wickham; Katarzyna Sitko; Maria Haarmans; John Read
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-06-12       Impact factor: 4.328

9.  Effects of Schedule I drug laws on neuroscience research and treatment innovation.

Authors:  David J Nutt; Leslie A King; David E Nichols
Journal:  Nat Rev Neurosci       Date:  2013-06-12       Impact factor: 34.870

10.  Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.

Authors:  K Macdonald; D Feifel
Journal:  Front Neurosci       Date:  2013-03-15       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.